

# Martin Griesshammer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1781818/publications.pdf>

Version: 2024-02-01

62  
papers

4,576  
citations

172386

29  
h-index

118793

62  
g-index

64  
all docs

64  
docs citations

64  
times ranked

2948  
citing authors

#	ARTICLE	IF	CITATIONS
1	Bleeding complications in <i>bcr</i>-negative myeloproliferative neoplasms (MPN): A retrospective single-center study of 829 MPN patients. <i>European Journal of Haematology</i> , 2022, 108, 154-162.	1.1	6
2	Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. <i>Lancet Haematology</i> , 2022, 9, e301-e311.	2.2	46
3	Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study. <i>Lancet Haematology</i> , 2022, 9, e480-e492.	2.2	18
4	Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN. <i>Leukemia</i> , 2021, 35, 628-631.	3.3	8
5	Interferon alpha for essential thrombocythemia during 34 high-risk pregnancies: outcome and safety. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1481-1491.	1.2	8
6	The management, outcome, and postpartum disease course of 41 pregnancies in 20 women with polycythemia vera. <i>European Journal of Haematology</i> , 2021, 107, 122-128.	1.1	6
7	Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients. <i>Leukemia</i> , 2021, 35, 2989-2993.	3.3	34
8	Primary Thromboprophylaxis in Patients with Malignancies: Daily Practice Recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO), the Society of Thrombosis and Hemostasis Research (GTH), and the Austrian Society of Hematology and Oncology (A-GHO). <i>Cancers</i> , 2021, 13, 2905.	1.7	7
9	A review of hydroxyurea-related cutaneous adverse events. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1-7.	1.0	7
10	Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low, intermediate, and high risk myelofibrosis in JUMP, a Phase 3b, expanded-access study. <i>Hematological Oncology</i> , 2021, 39, 558-566.	0.8	11
11	Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry. <i>Cancers</i> , 2021, 13, 4086.	1.7	17
12	Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies. <i>Annals of Hematology</i> , 2021, 100, 2707-2716.	0.8	11
13	Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet. <i>Lancet Haematology</i> , 2021, 8, e658-e665.	2.2	17
14	Second cancers in MPN: Survival analysis from an international study. <i>American Journal of Hematology</i> , 2020, 95, 295-301.	2.0	34
15	Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms. <i>Annals of Hematology</i> , 2020, 100, 2015-2022.	0.8	16
16	Ruxolitinib-Associated Infections in Polycythemia Vera: Review of the Literature, Clinical Significance, and Recommendations. <i>Cancers</i> , 2020, 12, 3132.	1.7	18
17	Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. <i>British Journal of Haematology</i> , 2020, 189, 888-903.	1.2	61
18	Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. <i>Lancet Haematology</i> , 2020, 7, e226-e237.	2.2	93

#	ARTICLE	IF	CITATIONS
19	Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. <i>Blood</i> , 2020, 135, 381-386.	0.6	18
20	Long-Term Effect of Ruxolitinib (RUX) in Inadequately Controlled Polycythemia Vera (PV) without Splenomegaly: 5-Year Results from the Phase 3 Response-2 Study. <i>Blood</i> , 2020, 136, 40-41.	0.6	5
21	Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. <i>Leukemia</i> , 2019, 33, 1996-2005.	3.3	67
22	Thromboembolic events in polycythemia vera. <i>Annals of Hematology</i> , 2019, 98, 1071-1082.	0.8	63
23	High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation. <i>Annals of Hematology</i> , 2019, 98, 93-100.	0.8	24
24	Frequency of Thrombosis Is Higher in MPN Patients Who Develop Second Cancer Than in Controls. <i>Blood</i> , 2019, 134, 4170-4170.	0.6	2
25	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. <i>Leukemia</i> , 2018, 32, 1057-1069.	3.3	415
26	Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies. <i>Annals of Hematology</i> , 2018, 97, 617-627.	0.8	23
27	Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. <i>Blood Cancer Journal</i> , 2018, 8, 25.	2.8	26
28	Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study. <i>Haematologica</i> , 2018, 103, 51-60.	1.7	58
29	Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide. <i>British Journal of Haematology</i> , 2018, 182, 279-284.	1.2	3
30	Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. <i>Annals of Hematology</i> , 2018, 97, 1591-1600.	0.8	53
31	Recommendations for the diagnosis and treatment of patients with polycythaemia vera. <i>European Journal of Haematology</i> , 2018, 101, 654-664.	1.1	11
32	Contemporary management of patients with <i>BCR-ABL1</i> -negative myeloproliferative neoplasms during pregnancy. <i>Expert Review of Hematology</i> , 2018, 11, 697-706.	1.0	41
33	Risk Factors for Secondary Cancer in a Case-Control Study on 1,259 Patients with Myeloproliferative Neoplasms. <i>Blood</i> , 2018, 132, 4279-4279.	0.6	1
34	Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV). <i>Blood</i> , 2018, 132, 1753-1753.	0.6	7
35	Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. <i>Annals of Hematology</i> , 2017, 96, 1113-1120.	0.8	68
36	Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. <i>Lancet Oncology</i> , The, 2017, 18, 88-99.	5.1	205

#	ARTICLE	IF	CITATIONS
37	A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia. <i>Leukemia Research</i> , 2017, 60, 11-17.	0.4	35
38	The <i>BCR-ABL1</i>-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1929-1938.	0.9	15
39	Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. <i>Haematologica</i> , 2016, 101, 821-829.	1.7	140
40	Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. <i>Haematologica</i> , 2016, 101, 1065-1073.	1.7	130
41	Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. <i>Haematologica</i> , 2016, 101, 926-931.	1.7	118
42	Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. <i>Journal of Clinical Oncology</i> , 2016, 34, 151-159.	0.8	56
43	Safety and Efficacy of Ruxolitinib for the Final Enrollment of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (N = 2233). <i>Blood</i> , 2016, 128, 3107-3107.	0.6	3
44	Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera. <i>New England Journal of Medicine</i> , 2015, 372, 426-435.	13.9	720
45	Current and future treatment options for polycythemia vera. <i>Annals of Hematology</i> , 2015, 94, 901-910.	0.8	47
46	The Effect of Ruxolitinib on White Blood Cell Counts in Patients with Polycythemia Vera: Results from the RESPONSE Trial. <i>Blood</i> , 2015, 126, 4070-4070.	0.6	2
47	A Phase-Ib/II Study of Ruxolitinib Plus Pomalidomide in Myelofibrosis. <i>Blood</i> , 2015, 126, 826-826.	0.6	9
48	Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (A-GHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.). <i>Annals of Hematology</i> , 2014, 93, 1953-1963.	0.8	64
49	Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 7026-7026.	0.8	12
50	RESPONSE 2: A phase 3b study evaluating the efficacy and safety of ruxolitinib in patients with hydroxyurea (HU)-resistant/intolerant polycythemia vera (PV) versus best available therapy (BAT).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS7128-TPS7128.	0.8	3
51	Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs. <i>Journal of Clinical Oncology</i> , 2012, 30, 4098-4103.	0.8	344
52	Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet. <i>Journal of Clinical Oncology</i> , 2011, 29, 761-770.	0.8	724
53	A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. <i>British Journal of Haematology</i> , 2010, 148, 961-963.	1.2	144
54	Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. <i>Blood</i> , 2009, 113, 4829-4833.	0.6	229

#	ARTICLE	IF	CITATIONS
55	Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy. Blood Reviews, 2008, 22, 235-245.	2.8	60
56	High-Resolution SNP-Array Profiling Discloses Novel Genomic Aberrations in BCR/ABL-Negative Myeloproliferative Neoplasms with Myelofibrosis. Blood, 2008, 112, 2794-2794.	0.6	0
57	Essential Thrombocythemia/Polycythemia Vera and Pregnancy: The Need for an Observational Study in Europe. Seminars in Thrombosis and Hemostasis, 2006, 32, 422-429.	1.5	77
58	Treatment with Pegylated Interferon Î± (PegIntron) for High-Risk Essential Thrombocythemia: Results of a Phase II Study.. Blood, 2004, 104, 1522-1522.	0.6	3
59	Reversal of Acquired von Willebrand Disease after Allogeneic Hematopoietic Stem Cell Transplantation in a Patient with High Risk Chronic Lymphocytic Leukemia.. Blood, 2004, 104, 4014-4014.	0.6	1
60	Acquired Thrombophilia in Pregnancy: Essential Thrombocythemia. Seminars in Thrombosis and Hemostasis, 2003, 29, 205-212.	1.5	32
61	9 Fertility, pregnancy and the management of myeloproliferative disorders. Best Practice and Research: Clinical Haematology, 1998, 11, 859-874.	1.1	36
62	Essential Thrombocythemia and Pregnancy. Leukemia and Lymphoma, 1996, 22, 57-63.	0.6	61